AbD Serotec’s New Anti-Idiotypic Antibodies
Complete the form below to unlock access to ALL audio articles.
AbD Serotec’s new anti-idiotypic antibodies specifically recognize the humanized monoclonal antibody Herceptin (Trastuzumab).
The antibodies can be used to measure the Herceptin levels in serum from patients, with potential uses in patient monitoring and preclinical research.
The anti-Herceptin antibodies are available in three formats to provide for a range of assay requirements; high affinity monovalent Fab antibodies, ultra-high affinity monovalent Fab antibodies, and fully human IgG1 antibodies for immunogenicity assays.
“In response to increasing demand for our antibodies recognizing Rituximab, we produced six new antibodies targeting Herceptin to compliment our product offering to CROs and researchers worldwide” said Market Segment Manager, Victoria Warltier.
The generation of novel anti-idiotypic antibodies using the strength of the HuCAL technology is an ongoing focus area for AbD Serotec, and in the pipeline are several further anti-idiotypic antibodies specific for marketed antibody drugs, to be launched within 2012.
AbD Serotec also offers custom anti-idiotypic antibody generation services.
Herceptin is a drug used in the treatment of HER2 positive breast cancer and other HER2 overexpressing cancers. It binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells.
The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells.
